Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small-Cell Lung Cancer: A Phase II Global Study
SHI Ou, JS Ahn, L De Petris, R Govindan… - Journal of clinical …, 2016 - ascopubs.org
Purpose Crizotinib confers improved progression-free survival compared with chemotherapy
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …
in anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC), but …
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix… - The Lancet …, 2016 - thelancet.com
Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Background ALK-rearranged non-small-cell lung cancer (NSCLC) is sensitive to ALK
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
tyrosine kinase inhibitors (ALK inhibitors) such as crizotinib, but resistance invariably …
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
SN Gettinger, LA Bazhenova, CJ Langer… - The Lancet …, 2016 - thelancet.com
Background Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic
drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational …
drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational …
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non–Small-Cell Lung Cancer Previously Treated …
L Crino, MJ Ahn, F De Marinis, HJM Groen… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Phase I data (ASCEND-1) showed ceritinib efficacy in patients with ALK-
rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and …
rearranged non–small-cell lung cancer (NSCLC), regardless of brain metastases status and …
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer
DA Fennell, Y Summers, J Cadranel, T Benepal… - Cancer treatment …, 2016 - Elsevier
The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …
Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase
WS Huang, S Liu, D Zou, M Thomas… - Journal of medicinal …, 2016 - ACS Publications
In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic
lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary …
lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary …
The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second-generation ALK inhibitors in preclinical models
S Zhang, R Anjum, R Squillace, S Nadworny… - Clinical Cancer …, 2016 - AACR
Purpose: Non–small cell lung cancers (NSCLCs) harboring ALK gene rearrangements
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …
(ALK+) typically become resistant to the first-generation anaplastic lymphoma kinase (ALK) …
Racial/ethnic disparities in genomic sequencing
Importance Although poorly understood, there is heterogeneity in the molecular biology of
cancer across race and ethnicities. The representation of racial minorities in large genomic …
cancer across race and ethnicities. The representation of racial minorities in large genomic …
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastasis
KL Johung, N Yeh, NB Desai, TM Williams… - Journal of Clinical …, 2016 - ascopubs.org
Purpose We performed a multi-institutional study to identify prognostic factors and determine
outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain …
outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain …